HSP70 (Heat Shock Protein 70) inducer therapies represent a promising neuroprotective strategy targeting the proteostasis network in neurodegenerative diseases[@heat2023]. HSP70 molecular chaperones play critical roles in protein folding, aggregate clearance, and cellular stress resistance. Enhancing HSP70 activity can mitigate proteostasis failure, a central hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other proteinopathies.
Mechanism of Action
HSP70 Biology
The HSP70 family includes multiple isoforms[@hspbased2022]:
HSPA1A/HSP70-1: Inducible stress response chaperone, primary target for pharmacological activation
HSPA8/Hsc70: Constitutively expressed chaperone involved in protein folding and [autophagy](/entities/autophagy)
BiP/GRP78: ER-resident HSP70 involved in [unfolded protein response](/entities/unfolded-protein-response)
HSP70 functions include:
ATP-dependent protein folding assistance
Aggregate disassembly and clearance
Co-chaperone regulation of client protein folding
Targeting misfolded proteins for autophagy or proteasomal degradation
Neuroprotective Mechanisms
...
Overview
HSP70 (Heat Shock Protein 70) inducer therapies represent a promising neuroprotective strategy targeting the proteostasis network in neurodegenerative diseases[@heat2023]. HSP70 molecular chaperones play critical roles in protein folding, aggregate clearance, and cellular stress resistance. Enhancing HSP70 activity can mitigate proteostasis failure, a central hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other proteinopathies.
Mechanism of Action
HSP70 Biology
The HSP70 family includes multiple isoforms[@hspbased2022]:
HSPA1A/HSP70-1: Inducible stress response chaperone, primary target for pharmacological activation
HSPA8/Hsc70: Constitutively expressed chaperone involved in protein folding and [autophagy](/entities/autophagy)
BiP/GRP78: ER-resident HSP70 involved in [unfolded protein response](/entities/unfolded-protein-response)
HSP70 functions include:
ATP-dependent protein folding assistance
Aggregate disassembly and clearance
Co-chaperone regulation of client protein folding
Targeting misfolded proteins for autophagy or proteasomal degradation
Neuroprotective Mechanisms
Aggregate clearance: HSP70 binds to misfolded proteins ([amyloid-beta](/proteins/amyloid-beta), [alpha-synuclein](/proteins/alpha-synuclein), [TDP-43](/proteins/tdp-43)) and facilitates their clearance via [autophagy](/mechanisms/autophagy)[@targeting2024]
Synaptic protection: Preserves synaptic proteins from misfolding and degradation
Mitochondrial protection: Protects mitochondrial proteins and reduces [ROS](/entities/reactive-oxygen-species) generation
Anti-inflammatory: Reduces [neuroinflammation](/mechanisms/neuroinflammation-pathway) by modulating microglial activation
Therapeutic Approaches
Small Molecule Inducers
Pharmacological upregulation of HSP70[@hsf2023]:
Geldanamycin derivatives (17-DMAG, 17-AAG): HSP90 inhibitors that indirectly activate HSF1 and increase HSP70 expression
HSF1 activators: Direct activation of heat shock factor 1 to drive HSP70 transcription
Geranylgeranylacetone (GGA): FDA-approved HSP70 inducer used for gastric ulcers, being repurposed for neurodegeneration
Natural Compounds
Dietary and plant-derived HSP70 inducers:
Curcumin: Polyphenol that activates HSF1 and upregulates HSP70
Resveratrol: SIRT1 activator that enhances HSP70 expression via AMPK pathway
Sulforaphane: NRF2 activator with secondary HSP70 induction
Peptide-Based Therapies
Tat-HSP70 fusion peptides: Cell-penetrating peptides that deliver functional HSP70 domains
Boss-C70: Engineered co-chaperone domain peptides that enhance HSP70 activity
Scoring
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 7 | Established target in oncology, relatively early for neurodegeneration | | Mechanistic Rationale | 9 | Direct proteostasis restoration, multi-disease relevance | | Root-Cause Coverage | 8 | Addresses protein aggregation at the chaperone level | | Delivery Feasibility | 7 | [BBB](/entities/blood-brain-barrier)-penetrating small molecules and natural compounds available | | Safety Plausibility | 8 | HSP70 induction is physiologically protective, good safety margin | | Combinability | 9 | Synergizes with autophagy inducers, proteasome modulators, anti-amyloid approaches | | Biomarker Availability | 7 | HSP70 levels can be measured in CSF and blood | | De-risking Path | 7 | Preclinical data strong; clinical trials in oncology de-risk safety | | Multi-disease Potential | 9 | AD, PD, ALS, Huntington's disease, FTD all have proteostasis deficits | | Patient Impact | 8 | Could benefit broad patient populations with proteinopathies | | Total | 72 | |